SAN FRANCISCO — California will receive a $7 million chunk of a multistate settlement with drug manufacturer GlaxoSmithKline PLC over its marketing of medications for asthma and depression.
The California Office of the Attorney General accused the company of promoting the drugs for off-label uses not approved by the Food and Drug Administration. In exchange for being released from those claims, GSK has agreed to pay a $105 million settlement to be divided up among California, 43 other states with a stake in the case, and the District of Columbia. The California complaint and the state’s settlement with GSK were both filed Wednesday in San Diego County Superior Court, and California received the largest share of the payout, according to the attorney general’s office.
